HK1025737A1 - Treatment of multiple sclerosis through ingestion of copolymer-1 - Google Patents
Treatment of multiple sclerosis through ingestion of copolymer-1Info
- Publication number
- HK1025737A1 HK1025737A1 HK00104810A HK00104810A HK1025737A1 HK 1025737 A1 HK1025737 A1 HK 1025737A1 HK 00104810 A HK00104810 A HK 00104810A HK 00104810 A HK00104810 A HK 00104810A HK 1025737 A1 HK1025737 A1 HK 1025737A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- treatment
- ingestion
- copolymer
- multiple sclerosis
- inhalation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- General Preparation And Processing Of Foods (AREA)
- Treatments Of Macromolecular Shaped Articles (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11998997A IL119989A0 (en) | 1997-01-10 | 1997-01-10 | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| PCT/US1998/000375 WO1998030227A1 (en) | 1997-01-10 | 1998-01-12 | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1025737A1 true HK1025737A1 (en) | 2000-11-24 |
Family
ID=11069682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK00104810A HK1025737A1 (en) | 1997-01-10 | 2000-08-01 | Treatment of multiple sclerosis through ingestion of copolymer-1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0975351B1 (zh) |
| JP (1) | JP4216342B2 (zh) |
| KR (1) | KR20000070058A (zh) |
| CN (1) | CN100528222C (zh) |
| AT (1) | ATE356608T1 (zh) |
| AU (1) | AU737287B2 (zh) |
| BR (1) | BRPI9807076B8 (zh) |
| CA (1) | CA2277365C (zh) |
| CZ (1) | CZ297983B6 (zh) |
| DE (1) | DE69837324T2 (zh) |
| EA (1) | EA003128B1 (zh) |
| HK (1) | HK1025737A1 (zh) |
| HU (1) | HU226612B1 (zh) |
| IL (2) | IL119989A0 (zh) |
| NZ (1) | NZ336690A (zh) |
| PL (1) | PL193300B1 (zh) |
| SK (1) | SK284029B6 (zh) |
| WO (1) | WO1998030227A1 (zh) |
| ZA (1) | ZA98214B (zh) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU766498B2 (en) * | 1998-07-23 | 2003-10-16 | President And Fellows Of Harvard College, The | Synthetic peptides and methods of use for autoimmune disease therapies |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6872739B1 (en) * | 1999-06-04 | 2005-03-29 | Vereniging Voor Christelijk Wetenshappelikjk Onderwijs | Use of riluzole for the treatment of multiple sclerosis |
| EP1552831B1 (en) * | 1999-06-04 | 2009-01-07 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Use of riluzole for treating multiple sclerosis |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| MXPA02008023A (es) * | 2000-02-18 | 2005-06-30 | Yeda Res & Dev | Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar. |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| IL153236A0 (en) * | 2000-06-05 | 2003-07-06 | Teva Pharma | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| ATE475883T1 (de) | 2001-12-04 | 2010-08-15 | Teva Pharma | Verfahren zur messung der wirkstärke von glatirameracetat |
| US20040009169A1 (en) | 2002-02-25 | 2004-01-15 | Julie Taylor | Administration of agents for the treatment of inflammation |
| WO2004066931A2 (en) * | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| WO2006029411A2 (en) | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| EA019998B9 (ru) | 2009-08-20 | 2016-01-29 | Йеда Рисерч Энд Дивелопмент Ко. Лтд. | Терапия глатирамером ацетатом с низкой кратностью |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| US8709433B2 (en) | 2010-10-11 | 2014-04-29 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate |
| CA2851510A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| CA2884267A1 (en) | 2012-10-10 | 2014-04-17 | Teva Pharmaceutical Industries Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| CN105884866B (zh) * | 2015-01-26 | 2021-04-20 | 漳州未名博欣生物医药有限公司 | 格拉替雷的化学合成方法 |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| WO2016172855A1 (zh) * | 2015-04-28 | 2016-11-03 | 深圳翰宇药业股份有限公司 | 多肽混合物高效液相色谱分析方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| US10323289B2 (en) | 2017-06-26 | 2019-06-18 | Institut Pasteur | Treatments to eliminate HIV reservoirs and reduce viral load |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5800808A (en) * | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US5719296A (en) * | 1995-10-30 | 1998-02-17 | Merck & Co., Inc. | Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins |
-
1997
- 1997-01-10 IL IL11998997A patent/IL119989A0/xx unknown
-
1998
- 1998-01-12 BR BRPI9807076A patent/BRPI9807076B8/pt not_active IP Right Cessation
- 1998-01-12 SK SK931-99A patent/SK284029B6/sk not_active IP Right Cessation
- 1998-01-12 CZ CZ0243799A patent/CZ297983B6/cs not_active IP Right Cessation
- 1998-01-12 CN CNB988031221A patent/CN100528222C/zh not_active Expired - Lifetime
- 1998-01-12 KR KR1019997006278A patent/KR20000070058A/ko active Search and Examination
- 1998-01-12 JP JP53110898A patent/JP4216342B2/ja not_active Expired - Lifetime
- 1998-01-12 DE DE69837324T patent/DE69837324T2/de not_active Expired - Lifetime
- 1998-01-12 NZ NZ336690A patent/NZ336690A/en not_active IP Right Cessation
- 1998-01-12 AT AT98901745T patent/ATE356608T1/de not_active IP Right Cessation
- 1998-01-12 CA CA2277365A patent/CA2277365C/en not_active Expired - Lifetime
- 1998-01-12 PL PL334566A patent/PL193300B1/pl unknown
- 1998-01-12 HU HU0001917A patent/HU226612B1/hu unknown
- 1998-01-12 WO PCT/US1998/000375 patent/WO1998030227A1/en active IP Right Grant
- 1998-01-12 EP EP98901745A patent/EP0975351B1/en not_active Expired - Lifetime
- 1998-01-12 AU AU58195/98A patent/AU737287B2/en not_active Expired
- 1998-01-12 EA EA199900621A patent/EA003128B1/ru not_active IP Right Cessation
- 1998-01-12 ZA ZA9800214A patent/ZA98214B/xx unknown
-
1999
- 1999-07-06 IL IL130820A patent/IL130820A/en not_active IP Right Cessation
-
2000
- 2000-08-01 HK HK00104810A patent/HK1025737A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL130820A (en) | 2007-03-08 |
| DE69837324D1 (de) | 2007-04-26 |
| HUP0001917A3 (en) | 2001-12-28 |
| JP4216342B2 (ja) | 2009-01-28 |
| BR9807076A (pt) | 2000-05-02 |
| WO1998030227A1 (en) | 1998-07-16 |
| CZ297983B6 (cs) | 2007-05-16 |
| CN1249690A (zh) | 2000-04-05 |
| EP0975351A1 (en) | 2000-02-02 |
| JP2001511121A (ja) | 2001-08-07 |
| EA199900621A1 (ru) | 2000-02-28 |
| SK284029B6 (sk) | 2004-08-03 |
| AU5819598A (en) | 1998-08-03 |
| PL334566A1 (en) | 2000-03-13 |
| AU737287B2 (en) | 2001-08-16 |
| CA2277365A1 (en) | 1998-07-16 |
| PL193300B1 (pl) | 2007-01-31 |
| ZA98214B (en) | 1999-08-11 |
| EP0975351B1 (en) | 2007-03-14 |
| DE69837324T2 (de) | 2007-11-29 |
| CA2277365C (en) | 2011-04-12 |
| ATE356608T1 (de) | 2007-04-15 |
| HUP0001917A2 (hu) | 2000-10-28 |
| EP0975351A4 (en) | 2002-05-15 |
| HU226612B1 (en) | 2009-04-28 |
| SK93199A3 (en) | 2000-11-07 |
| CN100528222C (zh) | 2009-08-19 |
| IL119989A0 (en) | 1997-04-15 |
| EA003128B1 (ru) | 2003-02-27 |
| BR9807076B1 (pt) | 2013-10-29 |
| NZ336690A (en) | 2001-05-25 |
| BRPI9807076B8 (pt) | 2021-05-25 |
| CZ243799A3 (cs) | 2000-06-14 |
| KR20000070058A (ko) | 2000-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA98214B (en) | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1. | |
| GB0129260D0 (en) | Pharmaceutical compositions and their uses | |
| BG103793A (en) | COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS | |
| UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
| ZA943744B (en) | Therapeutic substituted guanidines | |
| IL108007A (en) | USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | |
| HK1028568A1 (en) | Alpha-ketoamide multicatalytic protease inhibitors | |
| IL141157A0 (en) | Salt form of pantoprazole and pharmaceutical compositions containing the same | |
| WO1996021468A3 (en) | Chemically modified interferon | |
| MXPA02010458A (es) | Peptido modulador del receptor de trombopoyetina. | |
| AU4011300A (en) | Compositions and methods for the treatment of immune related diseases | |
| MXPA94009086A (es) | Guanidinas sustituidas terapeuticas. | |
| BG103632A (en) | Pharmaceutical compositions containing ibuprophene and domperidon for migraine treatment | |
| IL111805A0 (en) | Pharmaceutical compositions comprising dimeticone for the treatment of aphthae | |
| AU6849198A (en) | Neurotrypsin | |
| IL111804A0 (en) | Pharmaceutical compositions comprising dimeticone for the treatment of constipation | |
| EP0714404A4 (en) | ANTI-FLAMMABLE PEPTIDES | |
| GB9015774D0 (en) | Novel treatment | |
| GR1002385B (el) | Καθαρη μορφη στρεπτογραμινων, παρασκευη αυτης και φαρμακευτικες συνθεσεις που την περιεχουν. | |
| DE69929802D1 (en) | Lta4 hydrolase-hemmer | |
| TWI226833B (en) | Pharmaceutical composition for inhibiting bone resorption | |
| MY118194A (en) | Pharmaceutical compositions for use in inhibiting bone resorption |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE | Patent expired |
Effective date: 20180111 |